Drug Trial Radar · NCT01363388
A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis
Last checked: Nov 20, 2026Latest source record: Mar 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
67
Actual
Start
Sep 2011
Primary completion
Oct 2015
Study completion Jan 2016
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Jun 1, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this trial is to optimize the treatment to induce remission for patients with non-life-threatening anti-neutrophil cytoplasmic antibody vasculitis (AAV). The intent is to reduce the toxicity of induction therapy by reducing the overall exposure to or eliminating entirely the use of systemic corticosteroids during the induction period with an inhibitor of the complement C5a receptor plus cyclophosphamide or rituximab.
Conditions
- Vasculitis
Interventions
PlaceboDrug
BID for 84 days
CCX168Drug
BID for 84 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Subjects Achieving Disease Response at Day 85Time frame: Baseline to Day 85
Locations
44 sites in 10 countries. Site status is shown where the registry gives one.
Site not named
Feldkirch, Austria
Site not named
Innsbruck, Austria
Site not named
Linz, Austria
Site not named
Brussels, Belgium
Site not named
Edegem, Belgium
Site not named
Ghent, Belgium
Site not named
Leuven, Belgium
Site not named
Liège, Belgium
Site not named
Roeselare, Belgium
Site not named
Prague, Czechia
Site not named
Bordeaux, France
Site not named
Boulogne-sur-Mer, France
Site not named
Brest, France
Site not named
Colmar, France
Site not named
Grenoble, France
Site not named
Nantes, France
Site not named
Paris, France
Site not named
Saint-Jacques, France
Site not named
Valenciennes, France
Site not named
Berlin, Germany
Site not named
Cologne, Germany
Site not named
Dresden, Germany
Site not named
Freiburg im Breisgau, Germany
Site not named
Fulda, Germany
Site not named
Heidelberg, Germany
Site not named
Budapest, Hungary
Site not named
Groningen, Netherlands
Site not named
Leiden, Netherlands
Site not named
Rotterdam, Netherlands
Site not named
Utrecht, Netherlands
Site not named
Bialystok, Poland
Site not named
Katowice, Poland
Site not named
Szczecin, Poland
Site not named
Wroclaw, Poland
Site not named
Linköping, Sweden
Site not named
Lund, Sweden
Site not named
Malmö, Sweden
Site not named
Stockholm, Sweden
Site not named
Birmingham, United Kingdom
Site not named
Cambridge, United Kingdom
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.